drugset / Trial / NCT06846281
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
Timeline
- Start
- 2025-06-23
- Primary completion
- 2029-07-24
- Completion
- 2031-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ocrelizumab | Monoclonal antibody | 600 mg | Intravenous |
| Comparator | Ocrelizumab | Monoclonal antibody | 920 mg | Intravenous |
| Subject | Remibrutinib | Small molecule | — | Oral |